<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A5E72F91-30E2-45E6-8D19-EDC197FF970A"><gtr:id>A5E72F91-30E2-45E6-8D19-EDC197FF970A</gtr:id><gtr:name>Monash University</gtr:name><gtr:address><gtr:line1>Monash University</gtr:line1><gtr:line2>Level 1, Chancellery Building D</gtr:line2><gtr:line3>26 Sports Walk, Wellington Road</gtr:line3><gtr:postCode>3800</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/289F7529-FA9B-42C2-B4C7-4603DA25CC42"><gtr:id>289F7529-FA9B-42C2-B4C7-4603DA25CC42</gtr:id><gtr:name>Ludwig Institute for Cancer Research</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Northern Institute for Cancer Research</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A5E72F91-30E2-45E6-8D19-EDC197FF970A"><gtr:id>A5E72F91-30E2-45E6-8D19-EDC197FF970A</gtr:id><gtr:name>Monash University</gtr:name><gtr:address><gtr:line1>Monash University</gtr:line1><gtr:line2>Level 1, Chancellery Building D</gtr:line2><gtr:line3>26 Sports Walk, Wellington Road</gtr:line3><gtr:postCode>3800</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/289F7529-FA9B-42C2-B4C7-4603DA25CC42"><gtr:id>289F7529-FA9B-42C2-B4C7-4603DA25CC42</gtr:id><gtr:name>Ludwig Institute for Cancer Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DDB07FE7-2ED9-4228-8034-04699A414E04"><gtr:id>DDB07FE7-2ED9-4228-8034-04699A414E04</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:otherNames>Edward</gtr:otherNames><gtr:surname>Noble</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800014"><gtr:id>6D8C5A62-821A-4C67-BD21-5BA571E1CD23</gtr:id><gtr:title>Structure-function study of CDK complexes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800014</gtr:grantReference><gtr:abstractText>The growth and division of cells is strictly controlled at the molecular level by a series of enzymes that include the cyclin dependent protein kinases (CDKs). These enzymes are switched on and off in an orderly sequence to ensure that cell division starts and stops at the required time. Though closely related in sequence, biological studies of the different members of the CDK family have revealed that each has unique properties. Our work, using the technique of X-ray crystallography, allows us to see the structure of these molecules at atomic resolution and so to learn how they differ from each other. The first aim of our work is to identify the sequence patterns that characterise substrates of the CDK family. We can use these patterns to identify potential substrates encoded within the human genome. These studies will also identify substrates suitable for analysis by X-ray crystallography that will provide an understanding of how they interact with CDKs. CDK activity is regulated by CDK binding to members of the cyclin and CKS protein families. The second aim of our work is to use kinetic, biophysical and structural methods to provide explanations for how cyclins and CKS proteins regulate CDK activity. Aberrant CDK activity has been linked to cancer, neurological diseases, and rheumatoid arthritis. In recent years, understanding a particular defect that leads to disease has led to exciting new medicines directed towards a particular target (e.g. the drugs Gleevec, Iressa and Herceptin for cancer treatment). A number of CDK-selective inhibitors are in clinical trials for the treatment of cancer. These agents all act by binding to the CDK active site to block CDK activity. Compounds that block other interactions made by CDK/cyclin complexes represent an alternative target for CDK-directed therapies. The work described in this project, to elaborate the interactions that mediate the binding of substrates to CDKs and CDK-regulatory proteins, will aid the further development of such compounds and may also reveal additional targets for inhibitor development.</gtr:abstractText><gtr:technicalSummary>Cyclin-dependent protein kinases (CDKs) are implicated in many cellular regulatory processes, notably in the control of cell cycle progression and transcription. By definition, CDK activity requires association with an activating cyclin molecule, with many family members further activated by phosphorylation of a conserved threonine residue within the activation loop (Thr160 in CDK2). While CDK1 is the only cell-cycle regulatory CDK that appears to be essential for cell viability and development in multicellular organisms, knockout of other CDK family members gives rise to phenotypes that suggest family members may have specific roles associated with the phosphorylation of a unique set of substrates. The first aim of this project is to identify novel CDK1, CDK2 and CDK4-specific substrates by screening an unbiased cDNA library using an approach that has been previously used to identify CDK2 substrates. The second aim of this project is to further elaborate the structural basis of CDK substrate selectivity in CDK/cyclin and CDK/cyclin/regulator complexes. Specifically we will (i) employ screening and biochemical methods to characterise and compare the substrate selectivity of CDK1/, and CDK2/, and CDK4/cyclin complexes; (ii) establish how CDK1 selectivity is modulated by interaction with the Cdc28 kinase subunit regulators Cks1 and Cks2; (iii) elaborate the role of the cyclin B recruitment site in determining CDK1 substrate selectivity; and (iv) use X-ray crystallography to define in atomic detail the molecular interactions that dictate the substrate selectivity of CDK 1, 2 and 4 complexes identified through our screening (objectives i and ii) and biochemical/biophysical (objective iii) studies. Structure determination and functional characterisation of these various complexes will contribute to our further understanding of control of cell cycle progression and cell division.</gtr:technicalSummary><gtr:fund><gtr:end>2012-02-13</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>379482</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Characterisation of CDK-containing complexes</gtr:description><gtr:id>60567E1D-EB08-4701-90DD-75C467157F7D</gtr:id><gtr:impact>Structure determination of CDK4/cyclin D3 (PMID: 19237555) Structure determination of CDK1/Cks and CDK1/cyclin B/Cks complexes (MS in preparation).</gtr:impact><gtr:outcomeId>6632CC4E645-1</gtr:outcomeId><gtr:partnerContribution>(i) Provision of DNA constructs for protein expression (ii) Provision of cDNA expression library (iii) transfer of know-how relating to high throughput phosphorylation screen.</gtr:partnerContribution><gtr:piContribution>Structure determination of CDK4 and CDK1 complexes Biochemical and biophysical characterisation of CDK-containing complexes</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Institute for Cancer Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Branch</gtr:department><gtr:description>CDK/Cyclin interactions with ASPP family members</gtr:description><gtr:id>AAF09030-D5D4-4586-96FF-1293E199AABB</gtr:id><gtr:impact>Collaboration is multi-disciplinary: We provide expertise in working with CDK/Cyclin complexes, while our collaborators provide expertise with iASPP family members</gtr:impact><gtr:outcomeId>ZiT6dRoZfWX-1</gtr:outcomeId><gtr:partnerContribution>Biochemical and cell-biological characterisation of iASPP proteins, and the consequences of their phosphorylation by CDK1/Cyclin B</gtr:partnerContribution><gtr:piContribution>Prepared and provided CDK1/Cyclin B to enable phosphorylation of iASPP</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Monash University</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Institute of Pharmaceutical Sciences</gtr:department><gtr:description>EM of CDK2 and Skp2 containing complexes</gtr:description><gtr:id>8CE2B916-D131-4A82-AB80-72DEB45C6038</gtr:id><gtr:impact>Preliminary work completed preparatory to further data collection on cryo EM samples</gtr:impact><gtr:outcomeId>58c29d5b877115.61383662-1</gtr:outcomeId><gtr:partnerContribution>Hans and Dominika Elmlund hosted Richard's visit, provided access to the instrument, and recorded images of this complex and the inhibitory particle complexes. They further characterized the images to the point of obtaining a preliminary 3D reconstruction.</gtr:partnerContribution><gtr:piContribution>Richard Heath, a PDRA employed on our MRC program grant, prepared an homogenous complex of CDK2/CyclinA/Cks1/Skp1/Skp2. Using funds provided to promote collaboration by Newcastle University, Richard visited the group of Hans and Dominika Elmlund at Monash University and took negatively stained EM images from which a preliminary 3D reconstruction has been possible.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Department Open Days</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>71A712D6-30EB-465B-8EF5-1D4D5DC1958A</gtr:id><gtr:impact>Open Day posters and tours of the facilities informed schools and the general public about ongoing research. Talks and posters stimulated a lot of discussion and interest. Open Days well attended by year 12 and 13 students looking to study at Oxford and as a result a number of Open Day attendees said they now planned to apply.

Increase in requests for further information and in students applying for work experience placements.</gtr:impact><gtr:outcomeId>545bee1384a328.57584632</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>141370</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Centre Studentship</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>F60A7571-BEA6-4929-BA27-991F7CE8B917</gtr:id><gtr:outcomeId>VbKhQsriHRq0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Newcastle-Monash Seedcorn Award</gtr:description><gtr:fundingOrg>Newcastle University</gtr:fundingOrg><gtr:fundingRef>OSR/0190/MONA/MN01</gtr:fundingRef><gtr:id>644BBB3B-68F6-4517-9DE8-796581225A43</gtr:id><gtr:outcomeId>58c29e32b7bf43.55252173</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>551870</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant (G0900107)</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0900107</gtr:fundingRef><gtr:id>09034D96-BE3E-40CC-BDF9-508F08F4220C</gtr:id><gtr:outcomeId>7DBCDF011780</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1710496</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Program Grant</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0901526</gtr:fundingRef><gtr:id>22797421-D03D-44F2-AFAF-142D36B1A070</gtr:id><gtr:outcomeId>Wz4w3q4SvEE0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>CDK/cyclin D has been a target for structural biology for many years. We have identified and published protocols for preparing crystallizable CDK4/cyclin D complex, and conditions under which this can form diffraction-quality crystals</gtr:description><gtr:id>BD2431C2-1DB8-47FE-ADCD-204E9C3E7F2F</gtr:id><gtr:impact>This work is expected to enable structural studies of CDK4/cyclin D/inhibitor complexes in the academic and pharmaceutical communities.</gtr:impact><gtr:outcomeId>D5481327BF4</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Purification and crystallization strategy for CDK4/Cyclin D</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>CDK1 is expressed in baculovirus, while Cks1 and Cyclin B are expressed in E. coli. Complexes are built up and purified by exploiting affinity tags and subsequent gel-filtration.</gtr:description><gtr:id>E1B9598A-D9BC-4B4F-A28F-17C96C1E4854</gtr:id><gtr:impact>Currently being used to attempt co-crystallization with CDK inhibitors that have arisen from anticancer drug discovery programs</gtr:impact><gtr:outcomeId>rDzp5XeaRDv</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Purification and crystallization strategy for CDK1/Cks1 and CDK1/CyclinB/Cks1</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>22964252-1F90-4C5F-A21B-E7882D75E866</gtr:id><gtr:title>An inhibitor's-eye view of the ATP-binding site of CDKs in different regulatory states.</gtr:title><gtr:parentPublicationTitle>ACS chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fed83e90bf8d87dc8d03c7940fc46e4"><gtr:id>2fed83e90bf8d87dc8d03c7940fc46e4</gtr:id><gtr:otherNames>Echalier A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1554-8929</gtr:issn><gtr:outcomeId>545b50f554d050.74371820</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F4029E2-BE4B-42B7-9BE5-92579690FEBB</gtr:id><gtr:title>Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f6522850dbac1cd5f5201cc2b11b805"><gtr:id>0f6522850dbac1cd5f5201cc2b11b805</gtr:id><gtr:otherNames>Unterlass J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58c29a8d000dd0.03002282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59361ACA-AE01-4104-83E6-978CCF1629F7</gtr:id><gtr:title>Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c3b9c02800c86c026505b940f8da308"><gtr:id>7c3b9c02800c86c026505b940f8da308</gtr:id><gtr:otherNames>Coxon CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>58c29a8cc63228.43149332</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1693EAC-A046-4AD5-8BFC-B24061510F78</gtr:id><gtr:title>Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design.</gtr:title><gtr:parentPublicationTitle>The journal of physical chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/744299bbd6a37b7b64299593ac60c126"><gtr:id>744299bbd6a37b7b64299593ac60c126</gtr:id><gtr:otherNames>Tan YS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1948-7185</gtr:issn><gtr:outcomeId>58c29a8d2bdaf2.24110765</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98571BD0-B44B-445F-8095-3A3555BA8682</gtr:id><gtr:title>Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79f608465622159d0552333bad2a2893"><gtr:id>79f608465622159d0552333bad2a2893</gtr:id><gtr:otherNames>Lu M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>pm_14666_26_23623661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3494F84A-8199-4435-B764-D9A09B92CC63</gtr:id><gtr:title>The structural basis for control of eukaryotic protein kinases.</gtr:title><gtr:parentPublicationTitle>Annual review of biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a64145c472aa10129ba57d007a79ffb1"><gtr:id>a64145c472aa10129ba57d007a79ffb1</gtr:id><gtr:otherNames>Endicott JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4154</gtr:issn><gtr:outcomeId>pm_15680_20_22482904</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800014</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>